| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.AOG.0000227787.24587.D1 |
| P698 | PubMed publication ID | 16880307 |
| P50 | author | David Gershenson | Q57167281 |
| Anais Malpica | Q69964105 | ||
| Anil K. Sood | Q88114757 | ||
| Karen H. Lu | Q117217757 | ||
| P2093 | author name string | Robert L Coleman | |
| Charlotte C Sun | |||
| Michael T Deavers | |||
| Diane C Bodurka | |||
| Elvio G Silva | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | low-grade serous carcinoma | Q123750979 |
| P304 | page(s) | 361-368 | |
| P577 | publication date | 2006-08-01 | |
| P1433 | published in | Obstetrics and Gynecology | Q7075543 |
| P1476 | title | Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary | |
| P478 | volume | 108 |
| Q37104731 | A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. |
| Q35980522 | A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006 |
| Q34387999 | A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology |
| Q51160917 | Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. |
| Q95933360 | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids |
| Q34162272 | BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas |
| Q88706778 | BRAFV600E mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary |
| Q35461505 | Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer |
| Q38367063 | CT features of low grade serous carcinoma of the ovary |
| Q57171169 | Characterization of ovarian cancer cells and tissues by Fourier transform infrared spectroscopy |
| Q37820754 | Classification of ovarian carcinomas based on pathology and molecular genetics |
| Q102141700 | Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan |
| Q34626854 | Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma |
| Q79825860 | Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma |
| Q100503056 | Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer |
| Q37232123 | Critical molecular abnormalities in high-grade serous carcinoma of the ovary |
| Q41516517 | DACT1 Overexpression in type I ovarian cancer inhibits malignant expansion and cis-platinum resistance by modulating canonical Wnt signalling and autophagy |
| Q37276915 | Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis |
| Q34424902 | Diagnosis, treatment, and follow-up of borderline ovarian tumors |
| Q92213748 | EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low |
| Q100449963 | Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors |
| Q36855239 | Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer |
| Q37025950 | Evaluating cell lines as tumour models by comparison of genomic profiles |
| Q53480219 | Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. |
| Q37604669 | Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC). |
| Q34604042 | Fallopian tube origin of supposed ovarian high-grade serous carcinomas |
| Q34066297 | GPR30 predicts poor survival for ovarian cancer |
| Q37094076 | Genetic and molecular changes in ovarian cancer |
| Q33598001 | Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer |
| Q64847268 | Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia |
| Q91971624 | Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient |
| Q50324389 | Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum |
| Q35510378 | Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum |
| Q48025617 | Hormone receptors and ovarian cancer survival |
| Q48709352 | Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non-invasive malignant serous ovarian tumors |
| Q35947034 | Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. |
| Q38372474 | Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. |
| Q36750622 | Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. |
| Q54980568 | Individualized Medicine in Ovarian Cancer: Are We There Yet? |
| Q35060446 | Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas |
| Q37988903 | Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum). |
| Q64076294 | Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer |
| Q91812790 | Low Grade Ovarian Serous Carcinoma - A Clinical-Morphologic Study |
| Q57155514 | Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions |
| Q58592773 | Low-grade Serous Ovarian Carcinoma |
| Q38068618 | Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles |
| Q89451359 | Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes |
| Q50856533 | Low-grade serous carcinoma of the ovary or peritoneum. |
| Q38514737 | Low-grade serous carcinoma: molecular features and contemporary treatment strategies |
| Q38109432 | Low-grade serous carcinoma: new concepts and emerging therapies. |
| Q36415602 | Low-grade serous carcinomas of the ovary contain very few point mutations |
| Q38942767 | Low-grade serous ovarian cancer: A review |
| Q92858022 | Low-grade serous ovarian cancer: State of the science |
| Q37301334 | Low-grade serous ovarian cancer: a unique disease |
| Q83597688 | Low-grade serous primary peritoneal carcinoma |
| Q26777702 | Medical treatment of early stage and rare histological variants of epithelial ovarian cancer |
| Q35419057 | Microenvironment and pathogenesis of epithelial ovarian cancer |
| Q36805357 | Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma |
| Q33580777 | Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma |
| Q34565756 | Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach |
| Q37183300 | Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women |
| Q34729698 | Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum |
| Q39234288 | Networking for ovarian rare tumors: a significant breakthrough improving disease management. |
| Q53143668 | New insights into ovarian cancer pathology. |
| Q35983825 | Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer |
| Q50887636 | Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. |
| Q40344519 | Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer |
| Q34086819 | Ovarian cancer development and metastasis |
| Q37332480 | Ovarian cancer: genomic analysis. |
| Q35659945 | Ovarian cancer: opportunity for targeted therapy |
| Q37982940 | Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features |
| Q34998994 | Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems |
| Q38007297 | Ovarian low-grade serous carcinoma: a comprehensive update |
| Q30410498 | Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924 |
| Q92944163 | PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors |
| Q37329264 | PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas |
| Q37101060 | Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications |
| Q85112344 | Patterns of Low-grade Serous Carcinoma With Emphasis on the Nonepithelial-lined Spaces Pattern of Invasion and the Disorganized Orphan Papillae |
| Q47804434 | Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study. |
| Q83566218 | Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube |
| Q88663604 | Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? |
| Q36622857 | Recent progress in the diagnosis and treatment of ovarian cancer |
| Q37954582 | Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study |
| Q40349757 | Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine. |
| Q83636947 | Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant |
| Q92889830 | Role of cancer-associated fibroblasts in tumor structure, composition and the microenvironment in ovarian cancer |
| Q55078149 | Role of tumor microenvironment in ovarian cancer pathobiology. |
| Q33607622 | SOX2 is required to maintain cancer stem cells in ovarian cancer. |
| Q36768921 | Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study |
| Q64256318 | Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer |
| Q92967868 | Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base |
| Q34967339 | Survival in women with grade 1 serous ovarian carcinoma |
| Q38702245 | Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer. |
| Q51609396 | Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary. |
| Q38824065 | The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer |
| Q38096241 | The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. |
| Q82674487 | The heterogeneity of epithelial ovarian cancer: getting it right |
| Q35209365 | The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma |
| Q30405874 | The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. |
| Q97691128 | The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance |
| Q36751103 | The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer |
| Q35032309 | The transcriptomic profile of ovarian cancer grading |
| Q94550861 | The untapped potential of ascites in ovarian cancer research and treatment |
| Q80489408 | Time for action: a "sea change" in treatment strategies for rare types of epithelial ovarian cancer |
| Q33735170 | Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference. |
| Q38284239 | Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all. |
| Q37724181 | Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary |
| Q99578051 | mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population |
Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120
Search more.